{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:58:55Z","timestamp":1790812735294,"version":"4.1.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Introduction<\/jats:title><jats:p>Direct-acting antiviral drugs (DAAs) have changed the paradigm of hepatitis C therapy for both HCV\/HIV co-infected and HCV mono-infected patients. We aimed to describe the HCV continuum of care of HIV-infected patients treated in an HIV clinic after a free DAA program in Indonesia and identify factors correlated with sofosbuvir-daclatasvir (SOF-DCV) treatment failure.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>We did a retrospective cohort study of adult HIV\/HCV co-infected patients under routine HIV-care from November 2019 to April 2020 in the HIV integrated clinic of Cipto Mangunkusumo Hospital, Jakarta, Indonesia. We evaluated some factors correlated with sofosbuvir-daclatasvir treatment failure: gender, diabetes mellitus, previous IFN failure, cirrhosis, concomitant ribavirin use, high baseline HCV-RNA, and low CD4 cell count.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results and discussion<\/jats:title><jats:p>Overall, 640 anti-HCV positive patients were included in the study. Most of them were male (88.3%) and former intravenous drug users (76.6%) with a mean age of 40.95 (SD 4.60) years old. Numbers and percentages for the stages of the HCV continuum of care were as follows: HCV-RNA tested (411; 64.2%), pre-therapeutic evaluation done (271; 42.3%), HCV treatment initiated (210; 32.8%), HCV treatment completed (207; 32.2%), but only 178 of these patients had follow-up HCV-RNA tests to allow SVR assessment; and finally SVR12 achieved (178; 27.8%). For the 184 who completed SOF-DCV treatment, SVR12 was achieved by 95.7%. In multivariate analysis, diabetes mellitus remained a significant factor correlated with SOF-DCV treatment failure (adjusted RR 17.0, 95%CI: 3.28\u201388.23, p = 0.001).<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>This study found that in the HCV continuum of care for HIV\/HCV co-infected patients, gaps still exist at all stages. As the most commonly used DAA combination, sofosbuvir daclatasvir treatment proved to be effective and well-tolerated in HIV\/HCV co-infected patients. Diabetes mellitus was significant factor correlated with not achieving SVR12 in this population.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0256164","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T19:02:49Z","timestamp":1628794969000},"page":"e0256164","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-0559","authenticated-orcid":true,"given":"Evy","family":"Yunihastuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmat","family":"Hariyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri Sanityoso","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-803X","authenticated-orcid":true,"given":"Kuntjoro","family":"Harimurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"issue":"9939","key":"pone.0256164.ref001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration","volume":"384","author":"CJ Smith","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"pone.0256164.ref002","first-page":"68","article-title":"Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia Pacific region: A systematic review and meta-analysis","volume":"18","author":"M Martinello","year":"2016","journal-title":"AIDS Rev"},{"issue":"6","key":"pone.0256164.ref003","first-page":"368","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"12","author":"JG Bartlett","year":"2004","journal-title":"Infect Dis Clin Pract"},{"issue":"9","key":"pone.0256164.ref004","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/jgh.15051","article-title":"Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis","volume":"35","author":"YX Zheng","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0256164.ref005","author":"I Hasan","year":"2017"},{"key":"pone.0256164.ref006","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","author":"World Health Organization (WHO)","year":"2018"},{"key":"pone.0256164.ref007","doi-asserted-by":"crossref","first-page":"e003767","DOI":"10.1136\/bmjgh-2020-003767","article-title":"Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: The road to elimination","volume":"5","author":"CE Boeke","year":"2020","journal-title":"BMJ Glob Heal."},{"key":"pone.0256164.ref008","author":"World Health Organization","year":"2018"},{"issue":"372","key":"pone.0256164.ref009","first-page":"1","article-title":"Diagnostic performance of APRI and FIB-4 for confirming cirrhosis in Indonesian HIV\/HCV co-infected patients","volume":"20","author":"E Yunihastuti","year":"2020","journal-title":"BMC Infect Dis."},{"issue":"21","key":"pone.0256164.ref010","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"DL Thomas","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0256164.ref011","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hiv.12711","article-title":"Establishing a hepatitis C continuum of care among HIV\/hepatitis C virus-coinfected individuals in EuroSIDA.","volume":"20","author":"S Amele","year":"2019","journal-title":"HIV Med"},{"issue":"10","key":"pone.0256164.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofz361","article-title":"Implementing a comprehensive hepatitis C virus (HCV) clinic within a human immunodeficiency virus clinic: a model of care for HCV microelimination","volume":"6","author":"C Rizk","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"pone.0256164.ref013","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/cid\/cix1004","article-title":"High treatment uptake in human immunodeficiency virus\/ hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands","volume":"66","author":"A Boerekamps","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0256164.ref014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.idc.2018.02.005","article-title":"Hepatitis C virus elimination in the human immunodeficiency virus\u2013coinfected population: leveraging the existing human immunodeficiency virus infrastructure.","volume":"32","author":"ME Clement","year":"2018","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"pone.0256164.ref015","doi-asserted-by":"crossref","first-page":"e0228847","DOI":"10.1371\/journal.pone.0228847","article-title":"Real-world efficacy of direct acting antiviral therapies in patients with HIV\/HCV","volume":"15","author":"SV Patel","year":"2020","journal-title":"PLoS One."},{"issue":"7","key":"pone.0256164.ref016","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jvh.13281","article-title":"Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort of 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).","volume":"27","author":"AC Miranda","year":"2020","journal-title":"J Viral Hepat"},{"issue":"11","key":"pone.0256164.ref017","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s10620-018-5215-0","article-title":"Similar sustained virologic response in real-world and clinical trial studies of hepatitis C\/human immunodeficiency virus coinfection","volume":"63","author":"C Sikavi","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"2","key":"pone.0256164.ref018","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.29071","article-title":"Eradication of hepatitis C virus and non-liver-related non\u2013acquired immune deficiency syndrome\u2013related events in human immunodeficiency virus\/hepatitis C virus coinfection","volume":"66","author":"J Berenguer","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"pone.0256164.ref019","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"L Milazzo","year":"2017","journal-title":"HIV Med"},{"issue":"12","key":"pone.0256164.ref020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice","volume":"64","author":"D Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0256164.ref021","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/liv.14232","article-title":"Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning","volume":"40","author":"A Trickey","journal-title":"Liver Int. 2020"},{"issue":"1","key":"pone.0256164.ref022","first-page":"1","article-title":"Insights on the Russian HCV care cascade: minimal HCV treatment for HIV\/HCV co-infected PWID in St. Petersburg","volume":"1","author":"JI Tsui","year":"2016","journal-title":"Hepatol Med Policy"},{"issue":"12","key":"pone.0256164.ref023","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/QAD.0000000000001566","article-title":"Succesful implementation of hepatitis C virus treatment in two large HIV clinics in Amsterdam: hepatitis C virus treatment cascade of care","volume":"31","author":"J Saris","year":"2017","journal-title":"AIDS"},{"issue":"4","key":"pone.0256164.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofaa085","article-title":"Hepatitis C care continuum in a human immunodeficiency virus (HIV) positive cohort: data from the HIV Atlanta Veterans Affairs cohort study","volume":"7","author":"RO Adekunle","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"pone.0256164.ref025","doi-asserted-by":"crossref","first-page":"e25062","DOI":"10.1002\/jia2.25062","article-title":"Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?","volume":"21","author":"NK Martin","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"pone.0256164.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0199174","article-title":"Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era","volume":"13","author":"A Zuckerman","year":"2018","journal-title":"PLoS One"},{"key":"pone.0256164.ref027","doi-asserted-by":"crossref","first-page":"e25051","DOI":"10.1002\/jia2.25051","article-title":"Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era","volume":"21","author":"R Sacks-Davis","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0256164.ref028","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"DR Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"pone.0256164.ref029","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12072-018-9868-8","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4","volume":"12","author":"A Abdel-Moneim","year":"2018","journal-title":"Hepatol Int"},{"issue":"4","key":"pone.0256164.ref030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.dld.2019.12.007","article-title":"Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV\/HCV co-infected subjects: Data from the ICONA\/HepaICONA foundation cohorts","volume":"52","author":"R Rossotti","year":"2020","journal-title":"Dig Liver Dis."},{"issue":"5","key":"pone.0256164.ref031","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C","volume":"48","author":"M Romero-G\u00f3mez","year":"2008","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0256164.ref032","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).","volume":"63","author":"V Leroy","year":"2016","journal-title":"Hepatology"},{"issue":"10","key":"pone.0256164.ref033","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"RT Chung","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0256164.ref034","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jvh.12630","article-title":"Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia","volume":"24","author":"N Durier","year":"2017","journal-title":"J Viral Hepat"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:46:08Z","timestamp":1699346768000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256164"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0256164","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}